Biotechnology
Commented by Nico Popp on July 11th, 2023 | 07:30 CEST
Returns thanks to e-prescription and co.: Redcare Pharmacy, BB Biotech, Cardiol Therapeutics
There are attractive returns to be had in the healthcare sector. Innovative approaches around data and biotechnology are particularly promising, according to Daniel Matviyenko, Portfolio Manager of Healthcare Strategies at Jennison Associates. But what does this innovation look like in concrete terms? And how can investors invest? We highlight the healthcare industry using three companies as examples, with a special focus on opportunities in select individual stocks.
Read
Commented by Armin Schulz on July 6th, 2023 | 07:55 CEST
TUI, Defence Therapeutics, Plug Power - Who has the potential for a rally?
The search for stocks with the potential for a rally is an exciting and promising task for investors. There are several approaches and strategies to find appropriate stocks. One commonly used approach is fundamental analysis, which examines a company's financial health, business models, growth prospects and other fundamental factors. Solid fundamental analysis can help identify companies with strong potential for future growth. We have chosen three companies with strong upside potential.
Read
Commented by André Will-Laudien on July 5th, 2023 | 07:55 CEST
666% rally in 5 years - can Nucera do even more? BioNTech, BioNxt Solutions, and Plug Power could be the winners!
The story of the Mainz-based biotech company BioNTech has set a precedent over the last 5 years. With a remaining gain of 666%, it still ranks among the best performers on the German stock market, even after a 75% price decline. Such movements usually take place on the NASDAQ, where it is easy for highly innovative technology or biotech stocks to raise the necessary growth capital. But not every stock market story is so positive. We go on a pearl diver's journey.
Read
Commented by André Will-Laudien on July 3rd, 2023 | 07:45 CEST
Forget the heating law - 100% turnaround opportunity possible with Deutsche Bank, Volkswagen, BYD and Cardiol Therapeutics
When the major indices perform, some stocks unfortunately fall by the wayside. This can be due to a lack of attractiveness or the impact of megatrends such as Artificial Intelligence or Digitalization. Deutsche Bank is well on track for 2023, Volkswagen's low valuation is bound to attract attention at some point, and biotech company Cardiol Therapeutics is poised for a big jump. We take a closer look.
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read
Commented by Juliane Zielonka on June 28th, 2023 | 07:40 CEST
Cardiol Therapeutics, Bayer, BASF - Sensational breakthroughs in medicine and sustainability
A study in the JACC journal shows that cardiovascular risk factors and diseases will increase sharply in the US. Ischemic heart disease is projected to increase by 31.1%, heart failure by 33.0% and myocardial infarction by 30.1%. Cardiol Therapeutics, a Canadian company specializing in cardiovascular diseases, is thus rapidly gaining in importance. Bayer goes AI and partners for the first time with a Swiss hospital for a digital solution that supports radiologists in diagnosis and treatment. BASF invests with its venture arm in the Swiss startup DePoly, which has developed an innovative chemical recycling technology. Discover the sustainable solution behind this investment here.
Read
Commented by Armin Schulz on June 26th, 2023 | 09:20 CEST
Bayer, BioNxt Solutions, BioNTech - Biotech facing a rebound?
Due to the Corona pandemic, the pharmaceutical and biotech sector received a lot of attention. Many investors invested too late and could hardly benefit from the significant upward movements. After the hype, a sense of disillusionment set in. The vaccine manufacturers felt the effects because as soon as the pandemic subsided, the stock market also went down. Large and small companies experienced sell-offs, with some trading below their cash reserves. These low prices led to a wave of takeovers. Most recently, Novartis snapped up the biotech company Chinook for up to USD 3.5 billion. Therefore, today, we look at three companies from the healthcare sector.
Read
Commented by Stefan Feulner on June 26th, 2023 | 08:50 CEST
Best conditions for a summer rally - Defence Therapeutics, SMA Solar, Rheinmetall
The German stock market reflects the current weather situation - bright to cloudy, with occasional dark clouds moving in, bringing thunderstorms and heavy rain. In the past few days, lightning struck companies such as Helma Eigenheimbau, Siemens Energy and Lanxess, which was reflected in price losses of well over 10%. Other companies were spared from the storm front and should continue to enjoy their place in the sun due to the positive news.
Read
Commented by Fabian Lorenz on June 21st, 2023 | 08:40 CEST
Biotech comeback! Profit with BioNTech, Morphosys and BioNxt Solutions
Biotech shares have not been among the favourites on the stock market in recent months. After the Corona hype, they were overshadowed by BigTech and especially AI. Sartorius, BioNTech and Co. have corrected strongly. But in the meantime, there are strong signs of a comeback - led by Morphosys. The share of the German biotech veteran has doubled since the beginning of April. MediGene and Evotec have also recorded price jumps. Are BioNTech and BioNxt Solutions next? Morphosys also continues to be praised by analysts. But Goldman Sachs wants to end the party.
Read
Commented by Fabian Lorenz on June 14th, 2023 | 07:00 CEST
Evotec, Morphosys, Defence Therapeutics: Strong biotech stocks
When thinking of strong biotech stocks in recent years, BioNTech likely came to mind initially. With the successful development of the COVID-19 vaccine, the Mainz-based company advanced to become the new industry high-flyer. But in the meantime, the Company has come back to reality. The coffers are bulging, but vaccine revenues are falling, and the development of the cancer pipeline will still take several years. Therefore, Evotec and Morphosys are currently celebrating a comeback. Analysts are hailing Evotec as the "Tesla of biotech," and price targets are rising. The Morphosys share has increased by more than 100% this year, and analysts believe the value is capable of even more. Due to positive news, investors can speculate on a rebound with Defence Therapeutics.
Read